BRPI0407280A - Granisetron transdérmico - Google Patents

Granisetron transdérmico

Info

Publication number
BRPI0407280A
BRPI0407280A BR0407280-4A BRPI0407280A BRPI0407280A BR PI0407280 A BRPI0407280 A BR PI0407280A BR PI0407280 A BRPI0407280 A BR PI0407280A BR PI0407280 A BRPI0407280 A BR PI0407280A
Authority
BR
Brazil
Prior art keywords
granisetron
transdermal
transdermal granisetron
patches
administration
Prior art date
Application number
BR0407280-4A
Other languages
English (en)
Inventor
Peter Altensch Pfer
Adam Charles Watkinson
Original Assignee
Strakan Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9952502&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0407280(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Strakan Ltd filed Critical Strakan Ltd
Publication of BRPI0407280A publication Critical patent/BRPI0407280A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"GRANISETRON TRANSDéRMICO". A presente invenção refere-se a emplastros adesivos para a administração transdérmica de granisetron, compreendem um adesivo acrílico contendo porções nucleofílicas não-acídicas que substancialmente aumentam o fluxo de granisetron através da pele.
BR0407280-4A 2003-02-05 2004-02-05 Granisetron transdérmico BRPI0407280A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0302662.2A GB0302662D0 (en) 2003-02-05 2003-02-05 Transdermal granisetron
PCT/GB2004/000403 WO2004069141A2 (en) 2003-02-05 2004-02-05 Transdermal granisetron

Publications (1)

Publication Number Publication Date
BRPI0407280A true BRPI0407280A (pt) 2006-01-31

Family

ID=9952502

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0407280-4A BRPI0407280A (pt) 2003-02-05 2004-02-05 Granisetron transdérmico

Country Status (32)

Country Link
US (3) US7608282B2 (pt)
EP (1) EP1589956B1 (pt)
JP (2) JP4146486B2 (pt)
KR (1) KR100893158B1 (pt)
CN (3) CN1747724A (pt)
AT (1) ATE368454T1 (pt)
AU (1) AU2004210181B2 (pt)
BR (1) BRPI0407280A (pt)
CA (1) CA2515094C (pt)
CR (1) CR7923A (pt)
CY (1) CY1106811T1 (pt)
DE (1) DE602004007888T2 (pt)
DK (1) DK1589956T3 (pt)
EC (1) ECSP055953A (pt)
ES (1) ES2287695T3 (pt)
GB (1) GB0302662D0 (pt)
GE (1) GEP20084390B (pt)
HR (1) HRP20050695B1 (pt)
IL (1) IL169881A (pt)
IS (1) IS7997A (pt)
MA (1) MA27616A1 (pt)
MX (1) MXPA05008343A (pt)
NO (1) NO331441B1 (pt)
NZ (1) NZ541103A (pt)
PL (1) PL218351B1 (pt)
PT (1) PT1589956E (pt)
RS (1) RS51696B (pt)
RU (1) RU2355387C2 (pt)
SI (1) SI1589956T1 (pt)
UA (1) UA83362C2 (pt)
WO (1) WO2004069141A2 (pt)
ZA (1) ZA200506128B (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5160018B2 (ja) 2002-06-25 2013-03-13 アクルックス・ディ・ディ・エス・プロプライエタリー・リミテッド 非晶質医薬組成物を用いる経皮送達速度調節
GB0302662D0 (en) * 2003-02-05 2003-03-12 Strakan Ltd Transdermal granisetron
US20070264319A1 (en) * 2004-09-01 2007-11-15 Lebo David B Transdermal Antiemesis Delivery System, Method and Composition Therefor
US20060263421A1 (en) * 2005-05-18 2006-11-23 Abeille Pharmaceuticals Inc Transdermal Method and Patch for Nausea
KR20130114229A (ko) 2005-06-03 2013-10-16 애크럭스 디디에스 피티와이 리미티드 경피 약물 전달 방법 및 조성물
CN100464752C (zh) * 2005-11-01 2009-03-04 中国人民解放军第二军医大学 格拉司琼巴布剂及其制法
EP1842541A1 (en) * 2006-03-29 2007-10-10 G.I.M.-Gesellschaft Für Innovative Medizin Gmbh Nfg Ohg Plant components and extracts and uses thereof
WO2008115599A1 (en) * 2007-03-21 2008-09-25 Alza Corporation Apparatus and method for transdermal delivery of a 5-hydroxytrytamine antagonist
US20080242696A1 (en) * 2007-03-27 2008-10-02 Chemagis Ltd. Crystalline granisetron base and production process therefor
JP2008297277A (ja) * 2007-06-01 2008-12-11 Taiyo Yakuhin Kogyo Kk 注射剤の安定化法
KR100929560B1 (ko) 2008-01-09 2009-12-03 에코 퍼시픽 엘티디 그라니세트론을 함유한 매트릭스 형태의 경피 흡수제
CN101721394B (zh) * 2008-10-29 2013-04-17 大连理工大学 一种格拉司琼和/或其盐酸盐贴剂
TW201021856A (en) 2008-12-01 2010-06-16 Genovate Biotechnology Co Ltd Antiemetic patch
CN101716163B (zh) * 2009-12-24 2013-07-31 沈阳药科大学 一种来曲唑靶向定位缓释透皮贴剂及其制备方法
CN101836949A (zh) * 2010-02-11 2010-09-22 上海现代药物制剂工程研究中心有限公司 含有止吐活性药物的透皮凝胶制剂及制备方法
US20110288115A1 (en) * 2010-05-24 2011-11-24 Avmedis Llc Treatment of vagally-mediated spectrum disorders
CN102293761B (zh) * 2010-06-22 2014-01-08 浙江省医学科学院 含止吐剂成份的透皮吸收贴剂
CN102462672B (zh) * 2010-11-17 2013-12-04 汪晴 一种雷莫司琼透皮贴剂及其制备方法
CN102178660B (zh) * 2011-04-19 2012-08-08 上海现代药物制剂工程研究中心有限公司 微孔型盐酸格拉司琼透皮贴膜及其制法
US9205060B2 (en) 2011-07-07 2015-12-08 Teikoku Seiyaku Co., Ltd. Adhesive skin patch containing serotonin receptor antagonist drug
CN106176742A (zh) * 2011-08-01 2016-12-07 江苏康倍得药业股份有限公司 适于透皮给药的含格拉司琼的药物组合物及其制备与应用
WO2014051055A1 (ja) * 2012-09-28 2014-04-03 東レ株式会社 キヌクリジンウレア誘導体及びその医薬用途
WO2015168210A1 (en) 2014-04-30 2015-11-05 Kimberly-Clark Worldwide, Inc. Transdermal drug delivery apparatus and methods
CN105520921B (zh) * 2015-01-09 2018-12-25 中国科学院理化技术研究所 一种含有格拉司琼的长效透皮贴剂
ES3001152T3 (es) 2016-12-20 2025-03-04 Lts Lohmann Therapie Systeme Ag Sistema terapéutico transdérmico que contiene asenapina y polisiloxano o poliisobutileno
PL3338768T3 (pl) 2016-12-20 2020-05-18 Lts Lohmann Therapie-Systeme Ag Transdermalny system terapeutyczny zawierający asenapinę
WO2019002204A1 (en) 2017-06-26 2019-01-03 Lts Lohmann Therapie-Systeme Ag TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ASENAPINE AND SILICONE-TYPE ACRYLIC HYBRID POLYMER
AU2019291060B2 (en) 2018-06-20 2024-09-05 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
EP3810099A1 (en) 2018-06-20 2021-04-28 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system containing asenapine
WO2020118091A1 (en) 2018-12-05 2020-06-11 Starton Therapeutics, Inc. Ondansetron in-adhesive transdermal patch
KR102537845B1 (ko) 2020-02-19 2023-05-30 신신제약 주식회사 그라니세트론을 함유하는 경피흡수제제

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3269994A (en) * 1963-09-30 1966-08-30 Catalin Corp Of America Solvent-resistant pressure-sensitive adhesive coating and method of producing the same
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
GB9214184D0 (en) * 1992-07-03 1992-08-12 Smithkline Beecham Plc Pharmaceuticals
US5989586A (en) 1992-10-05 1999-11-23 Cygnus, Inc. Two-phase matrix for sustained release drug delivery device
JPH10167956A (ja) * 1996-12-11 1998-06-23 Hisamitsu Pharmaceut Co Inc セロトニン受容体拮抗薬含有経皮投与製剤
JP2001513124A (ja) * 1997-02-21 2001-08-28 アドヒーシブズ リサーチ，インコーポレイテッド 感圧接着性薬剤透皮投与複合材とそれに使用する感圧接着性薬剤
WO1998053815A1 (en) * 1997-05-30 1998-12-03 Minnesota Mining And Manufacturing Company Transdermal drug delivery device for the delivery of tropisetron or granisetron
US6312715B1 (en) * 1998-05-01 2001-11-06 3M Innovative Properties Company Adhesive microsphere drug delivery composition
US6136807A (en) * 1998-11-10 2000-10-24 3M Innovative Properties Company Composition for the transdermal delivery of lerisetron
EP1150675B1 (en) 1999-02-09 2006-02-01 Samyang Corporation A transdermal composition of an antivomiting agent and a preparation containing the same
EP1044684B1 (en) * 1999-04-13 2004-07-28 Nitto Denko Corporation Percutaneously absorbable preparation
JP4378028B2 (ja) * 1999-04-13 2009-12-02 日東電工株式会社 経皮吸収型製剤
US6465004B1 (en) * 1999-06-05 2002-10-15 Noven Pharmaceuticals, Inc. Solubility enhancement of drugs in transdermal drug delivery systems and methods of use
DE19929197A1 (de) * 1999-06-25 2000-12-28 Novosis Pharma Ag Transdermalsysteme zur Abgabe von 5-HT3-Rezeptor-Antagonisten und ihre Verwendung zur antiemitischen Behandlung
DE10015783C2 (de) 2000-03-30 2003-12-04 Lohmann Therapie Syst Lts Transdermales therapeutisches System zur Abgabe von Lerisetron und seine Verwendung
KR100433614B1 (ko) * 2000-06-16 2004-05-31 주식회사 태평양 친수성 또는 염의 형태로 된 약물을 함유하는 경피흡수제제
US20020172712A1 (en) 2001-03-19 2002-11-21 Alan Drizen Antiemetic, anti-motion sustained release drug delivery system
GB0119012D0 (en) * 2001-08-03 2001-09-26 Strakan Group Plc Transdermal delivery of drugs
GB0302662D0 (en) * 2003-02-05 2003-03-12 Strakan Ltd Transdermal granisetron

Also Published As

Publication number Publication date
IL169881A0 (en) 2007-07-04
JP2008195738A (ja) 2008-08-28
UA83362C2 (uk) 2008-07-10
CN102416009A (zh) 2012-04-18
CN102526043A (zh) 2012-07-04
HRP20050695A2 (hr) 2006-02-28
JP4146486B2 (ja) 2008-09-10
ZA200506128B (en) 2006-12-27
US20100008974A1 (en) 2010-01-14
PL379027A1 (pl) 2006-06-26
AU2004210181A1 (en) 2004-08-19
MXPA05008343A (es) 2006-01-31
NO20053663D0 (no) 2005-07-28
HK1082199A1 (en) 2006-06-02
WO2004069141A3 (en) 2004-10-07
CY1106811T1 (el) 2012-05-23
JP2006516601A (ja) 2006-07-06
GEP20084390B (en) 2008-06-10
EP1589956B1 (en) 2007-08-01
WO2004069141A2 (en) 2004-08-19
NZ541103A (en) 2007-01-26
CA2515094C (en) 2008-12-09
RS51696B (sr) 2011-10-31
SI1589956T1 (sl) 2007-10-31
AU2004210181B2 (en) 2009-11-19
DE602004007888T2 (de) 2008-04-17
CR7923A (es) 2008-10-29
KR100893158B1 (ko) 2009-04-16
ES2287695T3 (es) 2007-12-16
AU2004210181A2 (en) 2004-08-19
RU2005127599A (ru) 2006-01-20
RS20050600A (sr) 2007-12-31
NO331441B1 (no) 2012-01-02
DK1589956T3 (da) 2007-10-01
IS7997A (is) 2005-08-24
US7608282B2 (en) 2009-10-27
WO2004069141B1 (en) 2004-12-23
US20120258164A1 (en) 2012-10-11
CA2515094A1 (en) 2004-08-19
DE602004007888D1 (en) 2007-09-13
EP1589956A2 (en) 2005-11-02
MA27616A1 (fr) 2005-11-01
NO20053663L (no) 2005-11-04
CN1747724A (zh) 2006-03-15
PL218351B1 (pl) 2014-11-28
GB0302662D0 (en) 2003-03-12
US20060177493A1 (en) 2006-08-10
ATE368454T1 (de) 2007-08-15
CN102416009B (zh) 2013-09-11
IL169881A (en) 2011-12-29
RU2355387C2 (ru) 2009-05-20
ECSP055953A (es) 2006-01-16
HRP20050695B1 (hr) 2013-11-08
KR20050116365A (ko) 2005-12-12
PT1589956E (pt) 2007-08-23

Similar Documents

Publication Publication Date Title
ECSP055953A (es) Granisetron transdermico
BR0315296A (pt) Derivados do ciclohexanol espirocìclicos
BRPI0901553A2 (pt) máscara facial
BRPI0608297A2 (pt) composições de lipossomos
GT200400264A (es) Agentes endoparasiticida para administracion topica
DK1802274T3 (da) Anvendelse af cannabidiol i inhibitionen af hjernetumorcellemigration
DK1797053T3 (da) Phenothiazinium-forbindelse til sårheling
BR0318278A (pt) compostos de éter aminocicloexìlico e usos dos mesmo
BRPI0508556A (pt) moduladores de canal iÈnico
ATE465724T1 (de) Transdermales therapeutisches system mit ionenpaar-mikroreservoiren
BRPI0620229A8 (pt) formulação
BR0314300A (pt) Aplicação de substâncias para a proteção da pele
BRPI0412655A (pt) dispositivo para auxiliar a terapia de hiperhidrose
IS2488B (is) Fyrirbygging á krabbameini í ristli og endaþarmi
MX2008001661A (es) Metodos para tratar afecciones malignas de celulas b que utilizan una molecula de fusion del activador de transmembrana o interactor del ligando de ciclofilina de modulacion de calcio-ig.
BRPI0520258A2 (pt) uso de uma composição farmacêutica, método para preparar uma composição farmacêutica, e, uso de uma quantidade eficaz de acetato de eslicarbazepina
ITMI20050477A1 (it) Cerotto transdermico
GT200500268A (es) Inhibidores de la adenilato ciclasa soluble
MXPA05009718A (es) Uso de un fibrato y orlistato para el tratamiento de obesidad.
BRPI0515115A (pt) método de tratar uma doença de pele proliferativa
BRPI0518139A (pt) formulações de gel de 4-hidróxi tamoxifeno
DK1389122T3 (da) Forebyggelse af epitelcancer
CR7618A (es) Metodos de tratamiento con inhibidores de la ptec y agentes antihipertensivos
DK1817029T3 (da) Isoxazolderivat til lindring af neuropatiske smerter

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements